Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDAGet Free Report) CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00. Following the transaction, the chief executive officer directly owned 1,198,095 shares in the company, valued at approximately $68,339,338.80. The trade was a 2.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

  • On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
  • On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
  • On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total transaction of $1,052,250.00.
  • On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total transaction of $1,002,500.00.
  • On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total transaction of $764,863.40.
  • On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $1,003,500.00.
  • On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total transaction of $132,000.00.
  • On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28.
  • On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $859,891.96.
  • On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Price Performance

Shares of LQDA opened at $56.93 on Friday. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $59.75. The company has a market capitalization of $5.06 billion, a price-to-earnings ratio of 406.67 and a beta of 0.41. The firm has a 50-day simple moving average of $39.70 and a 200-day simple moving average of $35.94. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.84 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDAGet Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, equities research analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia in the fourth quarter valued at about $25,000. Covestor Ltd increased its holdings in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in Liquidia in the third quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the third quarter valued at about $34,000. Finally, NewEdge Advisors LLC purchased a new position in Liquidia in the second quarter valued at about $25,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of recent analyst reports. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Finally, Needham & Company LLC raised their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Get Our Latest Stock Analysis on Liquidia

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

See Also

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.